Page 65 - Read Online
P. 65

Page 14 of 17                                                 Chan et al. Hepatoma Res 2018;4:5  I  http://dx.doi.org/10.20517/2394-5079.2017.49


               53.  Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ. Surgical treatment of hepatocellular carcinoma with portal vein tumor
                   thrombus. Ann Surg Oncol 2010;17:2073-80.
               54.  Tang QH, Li AJ, Yang GM, Lai EC, Zhou WP, Jiang ZH, Lau WY, Wu MC. Surgical resection versus conformal radiotherapy combined
                   with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg 2013;37:1362-70.
               55.  Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi
                   E, Makuuchi M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it
                   adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg 2013;257:929-37.
               56.  Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y. Report of the 19th
                   follow-up survey of primary liver cancer in Japan. Hepatol Res 2016;46:372-90.
               57.  Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor
                   thrombosis. World J Surg 2014;38:490-6.
               58.  Zhang YF, Le Y, Wei W, Zou RH, Wang JH, OuYang HY, Xiao CZ, Zhong XP, Shi M, Guo RP. Optimal surgical strategy for hepatocellular
                   carcinoma with portal vein tumor thrombus: a propensity score analysis. Oncotarget 2016;7:38845-56.
               59.  Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-200.
               60.  Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007;4:424-
                   32.
               61.  Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K. Small
                   hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79-83.
               62.  Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment
                   for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
               63.  Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M. Prospective
                   randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular
                   carcinoma. Hepatology 1997;26:1156-61.
               64.  Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, Rodes J. Transarterial embolization versus symptomatic
                   treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology
                   1998;27:1578-83.
               65.  Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, Van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A.
                   Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J
                   Hepatol 1998;29:129-34.
               66.  Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J; Barcelona Liver Cancer
                   Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a
                   randomised controlled trial. Lancet 2002;359:1734-9.
               67.  Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol
                   chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
               68.  Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves
                   survival. Hepatology 2003;37:429-42.
               69.  Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, Minqing X, Jiaying Y. Barcelona clinic liver cancer stage B hepatocellular
                   carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore) 2014;93:e180.
               70.  Lee YB, Lee DH, Cho Y, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim HC, Yi NJ, Lee KW, Suh KS, Chung JW, Kim YJ. Comparison of
                   transarterial chemoembolization and hepatic resection for large solitary hepatocellular carcinoma: a propensity score analysis. J Vasc Interv
                   Radiol 2015;26:651-9.
               71.  Nouso K, Kariyama K, Nakamura S, Oonishi A, Wakuta A, Oyama A, Ako S, Dohi C, Wada N, Morimoto Y, Takeuchi Y, Kuwaki K, Onishi
                   H, Ikeda F, Shiraha H, Takaki A, Okada H. Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular
                   carcinoma. J Gastroenterol Hepatol 2017;32:695-700.
               72.  Xue T, Le F, Chen R, Xie X, Zhang L, Ge N, Chen Y, Wang Y, Zhang B, Ye S, Ren Z. Transarterial chemoembolization for huge
                   hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol 2015;32:64.
               73.  Leng JJ, Xu YZ, Dong JH. Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-
                   analysis. ANZ J Surg 2016;86:816-20.
               74.  Ajit Y, Sudarsan H, Saumya G, Abhishek A, Navneet R, Piyush R, Anil A, Arun G. Transarterial chemoembolization in unresectable
                   hepatocellular carcinoma with portal vein thrombosis: a perspective on survival. Oman Med J 2014;29:430-6.
               75.  Chern MC, Chuang VP, Liang CT, Lin ZH, Kuo TM. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with
                   portal vein invasion: safety, efficacy, and prognostic factors. J Vasc Interv Radiol 2014;25:32-40.
               76.  Choi JW, Kim HC, Lee JH, Yu SJ, Kim YJ, Yoon JH, Jae HJ, Hur S, Lee M, Chung JW. Transarterial chemoembolization of hepatocellular
                   carcinoma with segmental portal vein tumour thrombus. Eur Radiol 2017;27:1448-58.
               77.  Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B,
                   Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-
                   eluting beads transcatheter arterial chemoembolization. Eur Radiol 2017;27:526-35.
               78.  Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, Li ZK, Qi F, Zhao C. Transarterial chemoembolization compared with conservative treatment
                   for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 2012;29:2992-7.
               79.  Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon
                   Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V
                   Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results
                   of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
   60   61   62   63   64   65   66   67   68   69   70